We have identified the mouse and rat homologs of human interleukin-22 receptor alpha 2 (IL-22Ra2) and compared the localization, structure, and expression of the encoding murine and human genes. The mouse IL-22Ra2-encoding gene is located on chromosome 10A3 between, like in human, the genes for interferon-gamma R1 and IL-20R1. It spans a region of approximately 10 kb therefore being three times shorter than the human gene. Although the overall gene structure in both species is similar, the mouse gene lacks a counterpart to the third coding exon of the human gene known to be alternatively spliced. Like in human, mouse and rat IL-22Ra2 exist only as soluble receptors as deduced from the lack of transmembrane and intracellular domains encoding sequences. Quantitative expression analyses showed, analogically to the human system, a limited tissue distribution of mouse IL-22Ra2 mRNA. Differential modulation of IL-22Ra2 mRNA expression was observed upon systemic inflammation in mice in spleen, thymus, and lymph node.
Introduction
Interferons, as well as interleukin (IL)-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29, exert their biological effects via members of the cytokine receptor family class 2 (CRF2). 1 This receptor family comprises mostly transmembrane glycoproteins composed of an extracellular, transmembrane, and intracellular part. The extracellular part consists of about 210 amino acids and comprises two tandem fibronectin type III domains with several conserved amino-acid positions important for secondary structure. Functional receptor complexes are composed of two particular receptor chains, receptor (R)1 and accessory R2, that are aggregated after ligand binding and, via their heterogeneous intracellular parts, transduce the ligand binding signal preferentially by pathways involving Janus kinases and signal transducers and activators of transcription (STATs). 1, 2 Additionally to these membrane-standing receptors, a limited number of soluble receptors matching the characteristics of the CRF2 extracellular parts exist. In general, soluble receptors can be produced by different mechanisms. In most cases they are generated by proteolytic cleavage of membrane-standing receptors or by differential splicing of membrane receptor mRNA precursors. Additionally, they can be encoded by independent genes. Recently, the only so far known soluble receptor of the CRF2 that is encoded by an independent gene was found by others and ourselves. It has been named IL-22Ra2, IL-22BP, CRF2-10, CRF2-s1, or ZcytoR16. [3] [4] [5] [6] Soluble receptors can have opposing effects in vivo. By binding their specific ligand they either prevent or support the ligand's action. A neutralizing effect results from competition with the signaling transmembrane counterparts for ligand binding especially at sites of ongoing immune reactions where the concentration of soluble receptor is high. Support of the ligand's action can be due to the ligand's protection from proteolytic cleavage and its approved systemic transport into specific tissues where the ligand can be released because of low concentrations of ligand and soluble receptor. Therefore, soluble receptors may mainly prevent the local action of cytokines while enhancing their systemic effects. 7, 8 IL-22Ra2 was described to exist in three different spice variants, variant 1 with 263 amino acids (aa) (also named CRF2-10L or CRF2-s1-long; National Center of Biotechnology Information (NCBI) accession number NM_052962), variant 2 with 231 aa (also named CRF2-10, CRF2-s1-short, or IL-22BP; NCBI accession number NM_181309), and the variant 3 with 130 aa (also named CRF2-10s; NCBI accession number NM_181310).
Little is known so far with respect to the biological role of IL-22Ra2. Splice variant 1 is mainly expressed in placenta. 5, 6 The producing cells within that tissue remain to be identified. Nothing is known also about the conditions (immunological reactions, diseases) that regulate the expression of this variant. Moreover, the ligand of variant 1 could not be found yet. It does not seem to be IL-22 (see below).
3 IL-22Ra2 transcript variant 2 is expressed by different tissues. Apart from placenta and mammary gland, skin, spleen, thymus, lung, and stomach express IL-22Ra2, although at lower levels. 3, 5, 6 For this variant, neither its cellular sources nor the conditions that regulate its expression are known. The ligand of IL-22Ra2 variant 2 was shown to be IL-22. [3] [4] [5] 9 Regarding the IL-22Ra2 transcript variant 3, nothing is known apart from the mRNA sequence. The predicted protein sequence suggests that this molecule may not bind any ligand. 4 IL-22 is a recently discovered cytokine of the IL-10 family. [10] [11] [12] Like all members of the IL-10 family, it is a secreted a-helical molecule. A major source of IL-22 is activated T and NK cells. 13 Neither resting nor activated monocytes or B cells express this cytokine. Among T cells, IL-22 expression was mainly detected in CD4 þ memory cells and after polarization toward the type 1 phenotype. 13 The signaling receptor complex for IL-22 consists of the transmembrane CRF2 members IL-22R1 and IL-10R2. 11, 12, 14 Although different cell lines have been shown to express functional cell-standing IL-22 receptor complex, little is known about the biological role of IL-22. In HepG2 human hepatoma cell line, IL-22 upregulated mRNA expression of acute phase reactants such as serum amyloid A (SAA), a1-antichymotrypsin, and haptoglobin. Rapid induction of SAA-specific mRNA was also observed in mice injected with murine IL-22. 11 Additionally, murine IL-22 induced mRNA expression of pancreatitis-associated protein 1 in pancreas acinar cells and in pancreas in vivo, a protein of unknown function. 15 These so far discovered effects of IL-22 suggest a mainly systemic role of this cytokine. It therefore appears probable that this systemic role of IL-22 might be made possible by the help of IL-22Ra2.
In order to extend in future the knowledge on the biological role of IL-22Ra2 and to generate a tool for its further investigation in vivo, this study aimed at cloning the murine counterpart of human IL-22Ra2.
Results

Identification of murine IL-22Ra2
A homology search with the human IL-22Ra2 variant 2 protein sequence as query versus translated database (tblastn) (NCBI database) identified a partial mRNA sequence (NCBI accession number XM_136951) predicted by automated computational analysis from an annotated mouse genomic sequence from chromosome 10A3 (NT_039491). Using a mouse (BALB/c) spleen cDNA library, we obtained the full-length mRNA sequence of murine IL-22Ra2 by 5 0 and 3 0 RACE (registered in the NCBI databases with accession number AJ555484 since April 2003).
The amplification of the coding sequence of murine IL22Ra2 from different mice tissues by PCR on reverse transcribed mRNA (RT-PCR) and sequencing of PCR products identified only one splice variant (Figure 1a) . Figure 1b shows a comparison of the coding regions of mouse IL-22Ra2 with human IL-22Ra2 variant 1. The murine sequence lacks a region that corresponds to the human mRNA part derived from exon 4, and therefore corresponds to the human IL-22Ra2 variant 2. Murine IL22Ra2 cDNA shows 69% sequence identity to human IL22Ra2 variant 1 and 78% sequence identity to human IL22Ra2 variant 2.
Interestingly, upon repeated amplifications, we identified a variation within the coding sequence of murine IL22Ra2 from different mice tissues at two nucleotide positions within the same mouse strain (BALB/c): at position 546 and position 684 (Figure 1b) . At position 564 we mostly detected G and in some cases A. The resulting coding triplet therefore can be either GGG or GGA, in both cases encoding glycine at amino-acid sequence position 188 (Figures 1b and 3) . At position 684, we detected G in most cases and in some cases C. The resulting coding triplet therefore can be either CAG or CAC, encoding histidine or glutamine, respectively, at amino-acid sequence position 228 (Figures 1b and 3) . Interestingly, these, at positions 564 and 684, less frequently occurring nucleotides (A and C, respectively) are identical to corresponding nucleotides in the genomic sequence available in the NCBI database that was derived from C57BL/6J mice. Very recently, a sequence of murine IL-22Ra2 cDNA was also described by the group of Chang that also seems to work on BALB/c mice (registered in the NCBI database as AF493604). 16 In this sequence, there is a G at positions 546 and 684. Interestingly, this sequence comprises a T at position 447, which is in contrast to the G in our sequence. G is also the corresponding nucleotide in the genomic sequence available in the NCBI database (C57BL/6J). This G/T substitution, and the resulting variation of the coding triplet (GAG versus GAT), would result in a different amino-acid sequence (glutamic acid versus aspartic acid at position 149) (Figures 1b and 3 ). Further, mice and mouse strains need to be analyzed in different laboratories to clarify the frequency of special nucleotides at the considered positions.
We also cloned and submitted to the NCBI databases the rat IL-22Ra2 sequence (registered under accession number AJ555485 since April 2003). Identically to the mouse counterpart, only one mRNA variant that corresponds to the human IL-22Ra2 variant 2 exists in this species (data not shown).
Genomic structure of the murine gene encoding IL-22Ra2 By mapping the murine IL-22Ra2 mRNA sequence onto the mouse genome draft, we identified the corresponding gene on chromosome 10A3 (Figure 2a) . This gene spans a region of approximately 11 kb and, like in human, lies between two other CRF2 family members, Ifngr and the human IL20R1 homolog gene (designed as Il20r1). Mouse Il22ra2 is situated only 13 kb away from Ifngr and 78 kb away from Il20r1 (Figure 2a) . Similarly, the rat Il22ra2 locus lies between the genes encoding IFNgR and IL-20R1 (data not shown). Mouse Il22ra2 is composed of five coding exons and four intermediate introns (Figure 2b ). All intron-exon boundaries match the GT/AG rule. Noncoding exons could not be clearly differentiated. The overall structure of the mouse gene is
Comparison of human and murine IL-22Ra2 B Weiss et al similar to the corresponding human gene. In fact, exons 2, 3, and 4, and the coding part of exon 5 have lengths identical to the corresponding exons of the human gene (Figures 1 and 2b) . However, no counterpart to the human exon 4 is present in the murine gene. This was also confirmed by an alignment of murine versus human genomic sequence (Figure 2c and d) . This supports the lack of a mouse counterpart to the human IL-22Ra2 splice variant 1.
Characterization of mouse IL-22Ra2 cDNA and predicted protein The full-length mouse IL-22Ra2 cDNA comprises an open reading frame of 693 base pairs (bp) length encoding a protein of 230 aa with a calculated molecular weight of 26.6 kDa ( Figure 3) . A hydrophobic signal peptide of 21 aa length was predicted to be the most probable; however, an alternative length of 18 aa was also calculated with a high probability. Assuming the 21-aalong signal peptide, the mature protein would be composed of 219 aa resulting in a predicted molecular mass of 24.1 kDa. Assuming the 18-aa-long signal peptide, the mature protein would be composed of 222 aa resulting in a predicted molecular mass of 24.6 kDa. Like the corresponding human protein, murine IL-22Ra2 has no transmembrane and intracellular domain. It contains five cysteines, of which four are conserved in most CRF2 members. The amino acids defined as important for secondary structure are conserved, and all eight amino acids characteristic of the CRF2 are present (Figure 3) . Six potential N-linked glycosylation sites could be identified (Figure 3) . Alignment of the protein sequences of mouse IL-22Ra2 and human IL-22Ra2 variant 1 revealed an identity of 58% and a similarity of 65% (Figure 3) . In contrast, alignment of the protein sequences of mouse IL-22Ra2 and human IL-22Ra2 variant 2 revealed an identity of 66% and a similarity of 75%.
Expression of IL-22Ra2 in murine tissues
The expression pattern of mouse IL-22Ra2 was investigated in various tissues from BALB/c mice by real-time RT-PCR analysis. As shown in Figure 4a , high IL-22Ra2 expression was found in lymph nodes from control mice. Lung, spleen, and thymus from these mice showed only weak expression, and no expression could be detected in . The nucleotide at position 447 that differs from previously described data 16 is indicated in italic. h, human; m, mouse.
Comparison of human and murine IL-22Ra2 B Weiss et al kidney, liver, and heart. At 3 h after i.p. lipopolysaccharide (LPS) treatment of mice, a 10-fold increase as well as a slight decrease of IL-22Ra2 expression was observed in thymus and lymph node, respectively. In another kinetic study, the expression of IL-22Ra2 was analyzed in immunological tissues like spleen and lymph node until 72 h post LPS injection. At 24 h, a decrease was observed in both tissues. For comparison with the human system, we analyzed the expression of human IL-22Ra2 variant 1 and 2. Figure 4c demonstrates that the constitutive expression pattern and extent in human is similar to that in mice. Immunological tissues like lymph node and spleen show a clear expression of IL-22Ra2. In our previous studies performed with the same method, we did not detect any IL-22Ra2 expression in resting or activated human primary immune cells (resting and LPS-stimulated monocytes, resting and Staphylococcus aureus-stimulated B cells, resting and anti-CD3 monoclonal antibodystimulated human T cells, resting and IL-2/IL-12-stimulated NK cells). 6 Similarly, the group of Renauld and co-workers 3 did not find any IL-22Ra2 expression in LPS-and anti-CD3 monoclonal antibody-stimulated peripheral mononuclear blood cells. However, the group of Yseel and co-workers 17 demonstrated IL-22Ra2 expression in human anti-CD40 antibody/IL-4-stimulated B cells isolated from tonsils and spleen. Considering all these data, the clear expression seen in our study in human and mouse spleen and lymph node may be due to the presence of particularly activated B cells. 
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Discussion
Our data show that murine IL-22Ra2 corresponds to the human IL-22Ra2 variant 2 as deduced from analyses of its mRNA and predicted protein sequence and expression pattern. The existence of a murine counterpart to the human variant 1 was excluded because of the lack of a sequence corresponding to human exon 4 in the murine genomic DNA. Moreover, our RT-PCR analyses did not deliver any evidence of the existence of a murine counterpart to the human variant 3. Further studies are needed to show whether murine IL-22Ra2 might undertake the function of all human variants in mice or whether the functions of human variant 1 and 3 are not necessary in the mouse system. This question, however, cannot be answered as long as the ligands for the human variant 1 and 3 are not identified. Wei et al 16 have demonstrated that mouse IL-22Ra2 binds to mouse IL-22. However, no data exist so far on the interaction of mouse IL-22Ra2 with other members of the interferon/IL-10 family. The current knowledge about IL-22Ra2 in mice, rat, and humans is summarized in Table 1 .
The knowledge about IL-22Ra2 seems to be very interesting for three reasons. First, IL-22Ra2 is the only known soluble receptor within the CRF2 that is encoded by an independent gene. Second, IL-22Ra2 might be necessary for systemic effects of IL-22, especially, as all effects of IL-22 described so far are systemic effects. Third, high concentration of IL-22Ra2 might be an appropriate tool for neutralization of corresponding members of the interferon/IL-10 family in research (mouse, rat) and therapeutic (human) approaches. The high stability of human IL-22-IL-22Ra2 variant 2 complexes demonstrates the feasibility of such approaches. 4 The future will show whether, like soluble TNF-a receptor and IL-18BP, one of the variants of IL-22Ra2 will find entry into the therapy of immune disorders.
Materials and methods
Bioinformatic tools
A bioinformatic search for sequences similar to the human IL-22Ra2 sequence was performed using NCBI , 30 s at 601C, and 1 min at 681C, followed by 30 cycles with 30 s at 941C, 30 s at 551C, and 1 min at 681C and a final extension phase at 681C for 5 min. PCR products were analyzed by 1-1.5% grade agarose (Gibco BRL, Eggenstein, Germany) gel electrophoresis and GelStar s nucleic acid gel stain (BioWhittaker, Rockland, ME, USA) as well as by the Agilent 2100 Bioanalyzer with associated BioSizing Software Version A.02.10 (SI270) using the DNA 1000 bp chip (Agilent Technologies). Sequencing of PCR products (IL-22Ra2 RACE products and coding sequences) was performed by the Gene Analysis Service GmbH (Berlin, Germany).
Mice treatment BALB/c mice were purchased from Charles River (Wilmington, MA, USA), and were used at the age of 84-112 days. Three female BALB/c mice were i.p. injected with PBS with or without 5 mg/g body weight LPS from Escherichia coli 0111:B4 (Sigma-Aldrich, Munich, Germany). After 3 h, mice were killed and the Comparison of human and murine IL-22Ra2 B Weiss et al following tissues were taken: lung, spleen, thymus, stomach, kidney, liver, heart, and lymph node from hind leg. Additionally, three male mice were i.p. injected with 5 mg/g body weight LPS (see above). Directly before (0 h) and 1, 3, 6, 24, 48, and 72 h after LPS challenge, mice were killed, and spleen samples and lymph nodes were taken. Tissues were immediately frozen in liquid nitrogen.
Quantitative gene expression analysis Murine tissue samples were mixed with lysing buffer (Invisorb s RNA Kit II, Invitek, Berlin, Germany), frozen, and homogenized during thawing with the help of the IKA Ultra Turrax T5FU tissue homogenizer (Jahnke & Kunkel, Stauffen, Germany). Total RNA was isolated using the Invisorb s RNA Kit II according to the supplier's specifications (Invitek). Total RNA panels from human tissues were obtained from BD Clontech Laboratories. The quality and quantity of RNA were analyzed using an RNA 6000 Nano Chip and the Agilent 2100 Bioanalyzer (Agilent Technologies). Reverse transcription of mRNA was performed as described previously. 6 Samples were then analyzed by TaqMant PCR using TaqMant universal master mix (Applied Biosystems, Weiterstadt, Germany) and the ABI Prismt 7900 Sequence Detection System (Applied Biosystems). The primers used and 6-carboxy-fluoresceine (FAM)/6-carboxy-tetramethyl-rhodamine (TAMRA) double-labeled probes are indicated in Table 2 . After initial activation of AmpliTaq DNA polymerase, thermal conditions in each of the 45 cycles were 15 s at 951C and 1 min at 601C. Gene expression data were calculated relative to housekeeping gene HPRT-1 as described previously. 6 
